InMed Pharmaceuticals INM Stock
InMed Pharmaceuticals Price Chart
InMed Pharmaceuticals INM Financial and Trading Overview
| InMed Pharmaceuticals stock price | 2.99 USD |
| Previous Close | 1.26 USD |
| Open | 1.27 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 4000 |
| Day's Range | 1.22 - 1.29 USD |
| 52 Week Range | 0.92 - 19.5 USD |
| Volume | 68.72K USD |
| Avg. Volume | 585.17K USD |
| Market Cap | 4.23M USD |
| Beta (5Y Monthly) | 1.05845 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.42 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
INM Valuation Measures
| Enterprise Value | -4939584 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.2032 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.8069012 |
| Price/Book (mrq) | 0.34121442 |
| Enterprise Value/Revenue | -2.112 |
| Enterprise Value/EBITDA | 0.47 |
Trading Information
InMed Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.05845 |
| 52-Week Change | -90.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.5 USD |
| 52 Week Low | 0.92 USD |
| 50-Day Moving Average | 1.26 USD |
| 200-Day Moving Average | 2.84 USD |
INM Share Statistics
| Avg. Volume (3 month) | 585.17K USD |
| Avg. Daily Volume (10-Days) | 124.12K USD |
| Shares Outstanding | 3.33M |
| Float | 3.31M |
| Short Ratio | 0.45 |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 3.48% |
| Shares Short | 49.32K |
| Short % of Float | 1.48% |
| Short % of Shares Outstanding | 1.47% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -457.83% |
| Gross Margin | 3.52% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -44.30% |
| Return on Equity (ttm) | -133.014% |
Income Statement
| Revenue (ttm) | 2.34M USD |
| Revenue Per Share (ttm) | 1.32 USD |
| Quarterly Revenue Growth (yoy) | 234.00% |
| Gross Profit (ttm) | 543.55K USD |
| EBITDA | -10507133 USD |
| Net Income Avi to Common (ttm) | -15479254 USD |
| Diluted EPS (ttm) | -16.25 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 9.65M USD |
| Total Cash Per Share (mrq) | 2.9 USD |
| Total Debt (mrq) | 496.37K USD |
| Total Debt/Equity (mrq) | 4.01 USD |
| Current Ratio (mrq) | 5.218 |
| Book Value Per Share (mrq) | 3.722 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10672512 USD |
| Levered Free Cash Flow (ttm) | -7031391 USD |
Profile of InMed Pharmaceuticals
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 815 West Hastings Street |
| ZIP | V6C 1B4 |
| Phone | N/A |
| Website | https://www.inmedpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Q&A For InMed Pharmaceuticals Stock
What is a current INM stock price?
InMed Pharmaceuticals INM stock price today per share is 2.99 USD.
How to purchase InMed Pharmaceuticals stock?
You can buy INM shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InMed Pharmaceuticals?
The stock symbol or ticker of InMed Pharmaceuticals is INM.
Which industry does the InMed Pharmaceuticals company belong to?
The InMed Pharmaceuticals industry is Biotechnology.
How many shares does InMed Pharmaceuticals have in circulation?
The max supply of InMed Pharmaceuticals shares is 1.21M.
What is InMed Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
InMed Pharmaceuticals PE Ratio is now.
What was InMed Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
InMed Pharmaceuticals EPS is -12.42 USD over the trailing 12 months.
Which sector does the InMed Pharmaceuticals company belong to?
The InMed Pharmaceuticals sector is Healthcare.
InMed Pharmaceuticals INM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Nasdaq Australia Completion Cap NQAUCCN | 1088.27 AUD 720.28 USD |
0
|
— — | 1083.1 AUD 716.86 USD | 1088.97 AUD 720.74 USD | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}